Vir Biotechnology发布靶向PSMA的Pro-Xten®双遮蔽T细胞衔接器VIR-5500治疗转移性前列腺癌的积极1期最新数据

美股速递
16 hours ago

Vir Biotechnology宣布其靶向前列腺特异性膜抗原(PSMA)的Pro-Xten®双遮蔽T细胞衔接器VIR-5500,在治疗转移性前列腺癌患者的1期临床试验中取得积极的最新结果。该创新疗法通过双重遮蔽技术精准激活T细胞对抗肿瘤细胞,最新数据显示其在安全性和耐受性方面表现良好,同时展现出令人鼓舞的抗肿瘤活性。这一进展为晚期前列腺癌患者提供了新的治疗希望,也标志着双特异性T细胞衔接器在实体瘤领域的重要突破。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10